AmberMeshellYatesMD(She/Her)
Pediatric Hematology & Oncology • Cambridge, MAPediatric Anemia and Red Blood Cell Hematology
Medical Director, Medical Affairs, Agios Pharmaceuticals
Dr. Yates is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
88 Sidney St
Cambridge, MA 02139- Is this information wrong?
Summary
- I am a board certified pediatric hematologist focused on hemoglobinopathies.
Education & Training
University of TennesseeFellowship, Pediatric Hematology/Oncology, 2006 - 2010- University of TennesseeResidency, Pediatrics, 2003 - 2006
LSU School of Medicine in ShreveportClass of 2003
Northeast Louisiana UniversityBS, Biology, Magna cum Laude, 1995 - 1999
Certifications & Licensure
TX State Medical License 2011 - 2025
TN State Medical License 2006 - 2013- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Medical Educators Institute American Society of Hematology, 2017
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- A Phase II Trial of Regadenoson in Sickle Cell Anemia Start of enrollment: 2013 Jul 01
- Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload Start of enrollment: 2015 Oct 21
- Shared-Decision Making for Hydroxyurea Start of enrollment: 2018 Jul 12
Publications & Presentations
PubMed
- 14 citationsCOVID-19 outcomes in a large pediatric hematology-oncology center in Houston, Texas.Kala Y. Kamdar, Taylor O Kim, Erin E Doherty, Thomas M Pfeiffer, Shawki L Qasim, Mary Nell Suell, Amber M Yates, Susan M. Blaney> ;Pediatric Hematology and Oncology. 2021 May 25
- 8 citationsEngaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial.Anna M Hood, Heather Strong, Cara Nwankwo, Yolanda Johnson, James Peugh, Constance A. Mara, Lisa M Shook, William B. Brinkman, Francis J. Real, Melissa Klein, Rogelle ...> ;JMIR Research Protocols. 2021 May 21
- 3 citationsLongitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.Parul Rai, Vijaya M. Joshi, Jason F. Goldberg, Amber M Yates, Victoria I Okhomina, Rhiannon R. Penkert, Kenneth I. Ataga, Guolian Kang, Jane S. Hankins> ;Blood Advances. 2021 Jan 12
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Clinical Practice Patterns for Hydroxyurea Initiation in Young Children with Sickle Cell DiseaseAmber M Yates, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Ndepth: A Randomized Controlled Trial of a Novel Dose-Prediction Equation to Determine Maximum Tolerated Dose for Hydroxyurea Therapy in Pediatric Patients with Sickle...Amber M Yates, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Authored Content
- Treatment Advances in Sickle Cell DiseaseOctober 2019
- Sickle Cell DiseaseMay 2019
- ASH 2018: How Social Media Has Helped My Career/Practice as a HematologistDecember 2018
- ASH 2018: How Social Media Has Helped My Career/Practice as a HematologistDecember 2018
- Join now to see all
Press Mentions
Social Media Can Help Doctors Stay up to DateDecember 11th, 2018
Committees
- Executive Committee Member, American Academy of Pediatrics Section of Hematology-Oncology 2018 - Present
Professional Memberships
- Fellow
- Member
- American Society of Pediatric Hematology-OncologyMember
Industry Relationships
- Medical Director, Agios PharmaceuticalsMedical Director (SCD), Global Medical AffairsDisclosure: Employment, Stickholder2021 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
